Pharmacokinetics of intravenous N-acetylcysteine in men at rest and during exercise

European Journal of Clinical Pharmacology

Volumn 60, Issue 10, 2004, Pages 717-723

  Brown, Malcolm ^a   Bjorksten, Andrew ^b   Medved, Ivan ^c   McKenna, Michael ^c  

^a AUSTIN HEALTH   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c VICTORIA UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE;

ADULT; ARTICLE; BLOOD ANALYSIS; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COVARIANCE; CYCLING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG SAFETY; EXERCISE; HUMAN; INCIDENCE; MALE; MEASUREMENT; MUSCLE FATIGUE; NORMAL HUMAN; PRIORITY JOURNAL; PROPHYLAXIS; REST; SIDE EFFECT; STATISTICAL SIGNIFICANCE;

ACETYLCYSTEINE; ADULT; DRUG STABILITY; EXERCISE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; REST; SOLUTIONS;

EID: 12444339796     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-004-0862-9     Document Type: Article

References (15)

1. Reid MB, Grubweiser GJ, Stokic DS, Koch SM, Reis AA (1994) N-acetylcysteine inhibits muscle fatigue in humans. J Clin Invest 94:2468-2474
2. Medved I, Brown MJ, Bjorksten AR, Leppik JA, Sostaric S, McKenna MJ (2003) N-acetylcysteine infusion alters blood redox status but not time to fatigue during intense exercise in humans. J Appl Physiol 94:1572-1582
3. Medved I, Brown MJ, Bjorksten AR, McKenna MJ (2004) Effects of intravenous N-acetylcysteine on time to fatigue and potassium regulation during prolonged cycling exercise. J Appl Physiol 96:211-217
4. Medved I, Brown MJ, Bjorksten AR, Murphy KT, Petersen AC, Sostaric S, Gong X, McKenna MJ (2004) N-acetylcysteine enhances muscle cysteine and glutathione availability and attenuates fatigue during prolonged exercise in endurance-trained individuals. J Appl Physiol 97:1477-1485
5. Borgstrom L, Kagedal B, Paulsen O (1986) Pharmacokinetics of N-acetylcysteine in man. Eur J Clin Pharmacol 31:217-222
6. Olsson B, Johansson M, Gabrielsson J, Bolme P (1988) Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine. Eur J Clin Pharmacol 34:77-82
7. Prescott LF, Donovan JW, Jarvie DR, Proudfoot AT (1989) The disposition kinetics of intravenous N-acetylcysteine in patients with paracetamol overdosage. Eur J Clin Pharmacol 37:501-506
8. Dawson AH, Henry DA, McEwan J (1989) Adverse reactions to N-acetylcysteine during treatment for paracetamol poisoning. Med J Aust 151:329-331
9. Mant TG, Tempowski JH, Volans GN, Talbot JC (1984) Adverse reactions to N-acetylcysteine and effects of overdose. Br Med J 289:217-219
10. Vaughan DP, Tucker GT (1975) General theory for rapidly establishing steady state drug concentrations using two consecutive constant rate intravenous infusions. Eur J Clin Pharmacol 9:235-238
11. Gibaldi M, Perrier D (1982) Pharmacokinetics. 2nd edn. Marcel Dekker, New York
12. Benet LZ (1972) General treatment of linear mammillary models with elimination from any compartment as used in pharmacokinetics. J Pharm Sci 61:536-541
13. Beal SL, Sheiner LB (1992) NONMEM user's guide. NONMEM project group, University of California, San Francisco
14. Bergeron R, Kjaer M, Simonson L, Bulow J, Skovgaard D, Hewlett H, Galbo H (2001) Splanchnic blood flow and hepatic glucose production in exercising humans: role of renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol 281:R1854-R1861
15. Neilsen HB, Clemmesen JO, Skak C, Ott P, Secher NH (2002) Attenuated hepatosplanchnic uptake of lactate during intense exercise in humans. J Appl Physiol 92:1677-1683